Thromb Haemost 2018; 118(09): 1637-1645
DOI: 10.1055/s-0038-1668521
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism

Nicholas S. Roetker
1  Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
2  OptumLabs Visiting Fellow, Cambridge, Massachusetts, United States
3  Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States
,
Pamela L. Lutsey
3  Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States
,
Neil A. Zakai
4  Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, United States
5  Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, United States
,
Alvaro Alonso
6  Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States
,
Terrence J. Adam
7  College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, United States
8  Institute for Health Informatics, University of Minnesota, Minneapolis, Minnesota, United States
,
Richard F. MacLehose
3  Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States
› Author Affiliations
Funding This work was supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants R01-HL122200 (A.A.) and R01-HL131579 (P.L.L.). The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.
Further Information

Publication History

16 May 2018

05 July 2018

Publication Date:
13 August 2018 (eFirst)

Abstract

Oral anticoagulants used for the primary treatment of venous thromboembolism (VTE) include warfarin and the more recently introduced direct oral anticoagulants (DOACs), including rivaroxaban, apixaban, dabigatran and edoxaban. Information on the comparative safety of these medications in routine clinical practice is lacking. We identified patients with diagnoses for VTE and prescriptions for oral anticoagulants using claims data from a large U.S. insurance database from 2012 to 2017. Marginal structural logistic models were used to examine associations between type of oral anticoagulant and risk of all-cause mortality. Of 62,431 enrolees in this analysis, 51% were female and the mean age was 61.9 years. Initial oral anticoagulant prescriptions were for warfarin (n = 35,704), rivaroxaban (n = 21,064) and apixaban (n = 5,663). A total of 1,791 deaths occurred within 6 months of the initial oral anticoagulant prescription. Risk of all-cause mortality was not associated with having a prescription for warfarin versus any DOAC or between any head-to-head DOAC comparisons. Also, associations generally did not vary when stratified by VTE type, sex, age, co-morbidities (including renal disease) or anti-platelet medication use. In this observational study, the associations with all-cause mortality comparing DOACs versus warfarin agree with results from previous clinical trials and observational studies, while the associations for head-to-head DOAC comparisons provide new information on the comparative safety of DOACs. Our findings suggest that other criteria such as patient preference, cost, recurrent VTE risk or bleeding risk should be used when determining the choice of anticoagulant for the primary treatment of VTE.

Supplementary Material